Pre-existing mucosal generated secretory IgA antibodies may prevent transmission of HIV. The present study aimed to characterize mucosal antibodies generated following topical vaccination with a novel mucosal adjuvant, angiotensin, in combination with a killed feline immunodeficiency virus vaccine used as a model antigen.Female outbred cats were vaccinated with Fel-O-Vax FIV vaccine agent combined with increasing concentrations of angiotensin applied topically to oral, vaginal and rectal surfaces weekly for six weeks.
Control animals received intramuscular vaccinations with the Fel-O-Vax FIV alone or with A. Mucosal secretions were evaluated for antibody responses against FIV-p24 antigen or HIV-gp120 antigen.Topical application of whole killed FIV virus with A induced substantial secretory IgA -antigp120 antibodies in oral, vaginal and rectal secretions across a wide ranges of A dose levels. Intramuscular vaccination of FIV antigen with A induced high levels of SIgA-anti-gp120 antibodies at vaginal and rectal sites. The topical application vaccination strategy elicited only very weak systemic immune responses.